Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Poitiers University Hospital

Status: Enrolling

Conditions: Waldenstrom's Macroglobulinaemia Refractory

Treatments: Drug: Venetoclax

Study type: Observational

Funder types: Other

Identifiers

NCT06200220

WAVE

Details and patient eligibility

About

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

Enrollment: 45 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Waldenstrom's macroglobulinemia
• Treatment with Venetoclax
• Non opposition

Exclusion Criteria: none